FDA clears Galil's cryotherapy for kidney cancer:
This article was originally published in Clinica
Executive Summary
Galil Medical has received US FDA 510(k) clearance to expand the use of its minimally invasive SeedNet Gold cryotherapy system to the treatment of kidney cancer. The product, previously cleared for treating prostate cancer, uses the company's ultra-thin CryoNeedles to provide a nephron-sparing approach for ablating cancerous kidney masses, says the Yokneam, Israel firm.